Published in Nat Rev Cancer on June 18, 2009
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery | NCT00424255
Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors | NCT00730470
BIBW 2992 (Afatinib) in Head & Neck Cancer | NCT00514943
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer | NCT00708214
Tanespimycin in Treating Patients With Stage III-IV Melanoma | NCT00087386
A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer | NCT00710736
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 4.51
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol (2010) 3.70
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A (2010) 2.85
MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res (2010) 2.83
The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer (2012) 2.79
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A (2009) 2.55
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell (2011) 2.23
Targeted therapies for breast cancer. J Clin Invest (2011) 2.22
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A (2011) 2.18
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res (2010) 1.92
Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and Rho GTPase signaling. J Cell Sci (2011) 1.90
Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res (2009) 1.86
Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One (2010) 1.86
Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med (2010) 1.81
The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer (2010) 1.80
IQGAP1 and its binding proteins control diverse biological functions. Cell Signal (2011) 1.77
Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol (2010) 1.69
Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst (2013) 1.65
HER2 as a therapeutic target in the gastric cancer: is it sufficient? Indian J Gastroenterol (2012) 1.58
Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal (2014) 1.49
Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. Bioconjug Chem (2011) 1.45
Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer (2012) 1.44
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med (2017) 1.43
MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther (2012) 1.40
Chromothripsis: chromosomes in crisis. Dev Cell (2012) 1.40
Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin. J Exp Clin Cancer Res (2016) 1.38
Antibody-linked spherical nucleic acids for cellular targeting. J Am Chem Soc (2012) 1.34
Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochim Biophys Acta (2010) 1.32
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther (2011) 1.31
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol (2013) 1.28
Evidence for archaic adaptive introgression in humans. Nat Rev Genet (2015) 1.28
ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res (2010) 1.24
The role of microRNAs in breast cancer migration, invasion and metastasis. Int J Mol Sci (2012) 1.24
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res (2011) 1.23
ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res (2011) 1.23
Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition. Neoplasia (2012) 1.22
Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer (2014) 1.22
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res (2012) 1.20
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res (2011) 1.18
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis (2013) 1.17
Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol (2011) 1.17
A haplotype at STAT2 Introgressed from neanderthals and serves as a candidate of positive selection in Papua New Guinea. Am J Hum Genet (2012) 1.15
Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol (2009) 1.14
Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther (2010) 1.14
Biology-driven cancer drug development: back to the future. BMC Biol (2010) 1.12
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. Int J Breast Cancer (2011) 1.10
DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther (2011) 1.08
Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst (2014) 1.08
Flotillins in receptor tyrosine kinase signaling and cancer. Cells (2014) 1.08
Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes. Diagn Pathol (2013) 1.07
Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer (2010) 1.07
RNA interference against hepatic epidermal growth factor receptor has suppressive effects on liver regeneration in rats. Am J Pathol (2010) 1.05
High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS One (2013) 1.05
In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther (2011) 1.05
Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget (2014) 1.05
Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis. J Biol Chem (2012) 1.05
The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer (2010) 1.05
Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS One (2013) 1.05
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene (2013) 1.04
SOX10 directly modulates ERBB3 transcription via an intronic neural crest enhancer. BMC Dev Biol (2011) 1.03
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci (2010) 1.03
ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget (2014) 1.02
erbB3 is an active tyrosine kinase capable of homo- and heterointeractions. Mol Cell Biol (2013) 1.02
Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. Elife (2013) 1.02
Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis (2010) 1.01
The cooperation between hMena overexpression and HER2 signalling in breast cancer. PLoS One (2010) 1.01
Regulation of ERBB3/HER3 signaling in cancer. Oncotarget (2014) 1.00
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol (2011) 1.00
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin Investig Drugs (2010) 0.99
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis (2012) 0.99
Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum. Mol Cell Biol (2011) 0.98
Targeting survivin in cancer: novel drug development approaches. BioDrugs (2014) 0.98
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget (2013) 0.97
Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene (2011) 0.97
A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth. Oncogene (2012) 0.96
Chemopreventive activity of vitamin E in breast cancer: a focus on γ- and δ-tocopherol. Nutrients (2011) 0.96
E3 ubiquitin ligases in ErbB receptor quantity control. Semin Cell Dev Biol (2010) 0.96
Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins. PLoS One (2011) 0.96
HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. Oncoscience (2014) 0.96
Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol (2013) 0.96
IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance. J Biol Chem (2011) 0.96
A growing family: adding mutated Erbb4 as a novel cancer target. Cell Cycle (2010) 0.95
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95
S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling. J Biol Chem (2013) 0.95
Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One (2013) 0.94
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EBioMedicine (2015) 0.94
Emerging antibody combinations in oncology. MAbs (2011) 0.94
Cell surface annexins regulate ADAM-mediated ectodomain shedding of proamphiregulin. Mol Biol Cell (2012) 0.94
Carbon source metabolism and its regulation in cancer cells. Crit Rev Eukaryot Gene Expr (2012) 0.94
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J Clin Oncol (2016) 0.93
Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J Steroid Biochem Mol Biol (2010) 0.93
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 17.08
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature (1995) 9.03
Phosphoinositide kinases. Annu Rev Biochem (1998) 8.51
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 7.18
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol (2008) 6.90
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 6.78
Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A (1992) 6.61
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A (2003) 6.37
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
Oncogene addiction. Cancer Res (2008) 5.66
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell (2002) 5.64
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol (2003) 5.22
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res (2007) 5.01
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
HER-2 testing in breast cancer using parallel tissue-based methods. JAMA (2004) 4.60
A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell (2002) 4.57
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol (1994) 4.49
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell (2003) 4.23
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene (2008) 4.13
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst (2007) 4.03
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res (2008) 3.93
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell (2004) 3.79
Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J (1999) 3.79
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell (2006) 3.73
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol (2005) 3.62
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res (2001) 3.62
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol (1989) 3.62
HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer (2004) 3.50
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem (1994) 3.46
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell (2007) 3.46
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J (1994) 3.42
Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 3.40
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell (2003) 3.20
Structure of the extracellular region of HER3 reveals an interdomain tether. Science (2002) 3.19
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology (2001) 3.13
Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem (1996) 3.00
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol (2007) 2.79
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene (2008) 2.72
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 2.64
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell (2004) 2.60
Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res (1990) 2.56
ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol (2000) 2.53
Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer (2007) 2.41
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother (1993) 2.25
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J (2002) 2.17
Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res (2002) 2.07
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J (1997) 1.91
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med (2006) 1.83
ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett (2004) 1.79
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene (2008) 1.73
ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J (1998) 1.71
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
ErbB-3 predicts survival in ovarian cancer. J Clin Oncol (2006) 1.64
Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res (2003) 1.58
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem (2003) 1.56
A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol (2009) 1.54
The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle (2004) 1.54
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer Res (2002) 1.53
Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene (2003) 1.51
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res (2008) 1.50
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med (2012) 4.10
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest (2003) 4.06
Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol (2006) 3.62
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst (2011) 3.54
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol (2006) 2.93
Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst (2004) 2.72
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol (2012) 2.65
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 2.59
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol (2012) 2.34
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst (2013) 2.28
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res (2008) 1.83
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res (2002) 1.82
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin Cancer Res (2008) 1.81
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol (2004) 1.72
Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther (2007) 1.68
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol (2011) 1.56
The influence of a gene expression profile on breast cancer decisions. J Surg Oncol (2009) 1.52
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res (2008) 1.50
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol (2007) 1.50
Locally advanced and inflammatory breast cancer. J Clin Oncol (2008) 1.44
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res (2008) 1.42
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol (2005) 1.41
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
Amenorrhea from breast cancer therapy--not a matter of dose. N Engl J Med (2010) 1.40
Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. Radiology (2007) 1.24
ASCO's approach to a learning health care system in oncology. J Oncol Pract (2013) 1.22
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat (2010) 1.08
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer (2010) 1.08
Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? J Clin Oncol (2011) 1.05
Therapeutic strategies for triple-negative breast cancer. Cancer J (2008) 1.05
Clinical aspects of inflammatory breast cancer. Breast Dis (2006) 1.03
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res (2013) 1.02
Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Res Treat (2011) 1.01
Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol (2005) 1.00
Aromatase inhibitors--a triumph of translational oncology. N Engl J Med (2005) 1.00
Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep (2007) 0.98
Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol (2003) 0.98
Drug discount program. JAMA (2013) 0.97
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol (2010) 0.96
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res (2004) 0.95
Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res (2005) 0.94
The epothilones: translating from the laboratory to the clinic. Clin Cancer Res (2008) 0.93
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res (2004) 0.92
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.92
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. Oncology (2007) 0.88
A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trials. Oncologist (2012) 0.87
Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol (2006) 0.87
A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat (2006) 0.86
Concepts and clinical trials of dose-dense chemotherapy for breast cancer . Clin Breast Cancer (2005) 0.86
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs (2006) 0.86
A step in the right direction. J Clin Oncol (2006) 0.85
A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer (2006) 0.85
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res (2006) 0.84
Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer. Clin Breast Cancer (2012) 0.83
The impact of systemic therapy following ductal carcinoma in situ. J Natl Cancer Inst Monogr (2010) 0.83
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Invest New Drugs (2007) 0.83
Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer (2011) 0.83
CA 125 elevation in breast cancer: a case report and review of the literature. Breast J (2004) 0.82
Primary systemic chemotherapy for inflammatory breast cancer. Cancer (2010) 0.82
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer (2014) 0.82
Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia. Cancer Med (2013) 0.82
NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med (2013) 0.81
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat (2013) 0.81
Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. Anticancer Drugs (2013) 0.81
Cardiac dysfunction after cancer treatment. Tex Heart Inst J (2011) 0.80
Contralateral breast cancer: where does it all begin? J Clin Oncol (2005) 0.80
The heart of the matter. J Clin Oncol (2007) 0.80
Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opin Investig Drugs (2008) 0.80
Pertuzumab for the treatment of breast cancer. Cancer Invest (2014) 0.79
Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Semin Oncol (2002) 0.79
p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. Int J Oncol (2011) 0.79
Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin Emerg Drugs (2006) 0.78
Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. Expert Opin Biol Ther (2013) 0.78
Treatment of HER2-positive metastatic breast cancer. N Engl J Med (2015) 0.77
Treatment and cost implications of pertuzumab. Am J Manag Care (2012) 0.77
Pazopanib for the treatment of breast cancer. Expert Opin Investig Drugs (2012) 0.76
A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer. Clin Breast Cancer (2005) 0.76
Meta-analysis: should it be more than the sum of its parts? J Natl Cancer Inst (2010) 0.75
Pertuzumab: increasing the options. Oncology (Williston Park) (2014) 0.75
First, do no harm. Onkologie (2008) 0.75
Oophorectomy in carriers of BRCA mutations. N Engl J Med (2002) 0.75
Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer. Clin Breast Cancer (2004) 0.75
Avastin withdrawal symptoms. Expert Opin Pharmacother (2012) 0.75